Resveratrol, by modulating RNA processing factor levels, can influence the alternative splicing of Pre-mRNAs

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Markus, M Andrea ^a   Marques, Francine Z ^a   Morris, Brian J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD44V ANTIGEN; CD44V5 ANTIGEN; CELL PROTEIN; HUR PROTEIN; MESSENGER RNA; PROTEIN ASF; PROTEIN PTB1; PROTEIN RBM4; RESVERATROL; RNA PRECURSOR; SIRTUIN 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; NUCLEAR PROTEIN; RNA BINDING PROTEIN; SERINE ARGININE RICH SPLICING PROTEINS; SERINE-ARGININE-RICH SPLICING PROTEINS; SIRT1 PROTEIN, HUMAN; STILBENE DERIVATIVE;

AGAR GEL ELECTROPHORESIS; ALTERNATIVE RNA SPLICING; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; EXON; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; QUANTITATIVE STUDY; RNA PROCESSING; SEPARATION TECHNIQUE; WESTERN BLOTTING; CELL STRAIN HEK293; DRUG EFFECT; GENETICS; HELA CELL; INTRACELLULAR SPACE; METABOLISM; PROTEIN TRANSPORT;

ALTERNATIVE SPLICING; EXONS; HEK293 CELLS; HELA CELLS; HUMANS; INTRACELLULAR SPACE; NUCLEAR PROTEINS; PROTEIN TRANSPORT; RNA PRECURSORS; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, MESSENGER; RNA-BINDING PROTEINS; SIRTUIN 1; STILBENES;

EID: 83255181729     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028926     Document Type: Article

References (45)

1. Caceres JF, Kornblihtt AR, (2002) Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet 18: 186-193.
2. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ, (2008) Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 40: 1413-1415.
3. Faustino NA, Cooper TA, (2003) Pre-mRNA splicing and human disease. Genes Dev 17: 419-437.
4. Ward AJ, Cooper TA, (2010) The pathobiology of splicing. J Pathol 220: 152-163.
5. Srebrow A, Kornblihtt AR, (2006) The connection between splicing and cancer. J Cell Sci 119: 2635-2641.
6. Cooper TA, Wan L, Dreyfuss G, (2009) RNA and disease. Cell 136: 777-793.
7. Bracco L, Kearsey J, (2003) The relevance of alternative RNA splicing to pharmacogenomics. Trends Biotechnol 21: 346-353.
8. Hagiwara M, (2005) Alternative splicing: a new drug target of the post-genome era. Biochim Biophys Acta 1754: 324-331.
9. Sumanasekera C, Watt DS, Stamm S, (2008) Substances that can change alternative splice-site selection. Biochem Soc Trans 36: 483-490.
10. Shi J, Hu Z, Pabon K, Scotto KW, (2008) Caffeine regulates alternative splicing in a subset of cancer-associated genes: a role for SC35. Mol Cell Biol 28: 883-895.
11. Johnstone RW, (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287-299.
12. Baur JA, Sinclair DA, (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506.
13. Harikumar KB, Aggarwal BB, (2008) Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 7: 1020-1035.
14. Anekonda TS, (2006) Resveratrol-a boon for treating Alzheimer's disease? Brain Res Rev 52: 316-326.
15. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342.
16. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, et al. (2004) Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430: 686-689.
17. Guarente L, Picard F, (2005) Calorie restriction-the SIR2 connection. Cell 120: 473-482.
18. Beher D, Wu J, Cumine S, Kim KW, Lu SC, et al. (2009) Resveratrol is Not a Direct Activator of SIRT1 Enzyme Activity. Chem Biol Drug Des 74: 619-624.
19. Pacholec M, Chrunyk BA, Cunningham D, Flynn D, Griffith DA, et al. (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285: 8340-8351.
20. Morris BJ, (2005) A forkhead in the road to longevity: the molecular basis of lifespan becomes clearer. [Invited Review]. J Hypertens 23: 1285-1309.
21. Haigis MC, Sinclair DA, (2010) Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 5: 253-295.
22. Pozo-Guisado E, Lorenzo-Benayas MJ, Fernandez-Salguero PM, (2004) Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation. Int J Cancer 109: 167-173.
23. Canto C, Auwerx J, (2009) PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 20: 98-105.
24. Greer EL, Brunet A, (2009) Different Dietary Restriction Regimens Extend Lifespan by both Independent and Overlapping Genetic Pathways in C. elegans. Aging Cell 8: 113-127.
25. Usha S, Johnson IM, Malathi R, (2005) Interaction of resveratrol and genistein with nucleic acids. J Biochem Mol Biol 38: 198-205.
26. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, et al. (2003) Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 302: 2141-2144.
27. Sakla MS, Lorson CL, (2008) Induction of full-length survival motor neuron by polyphenol botanical compounds. Hum Genet 122: 635-643.
28. Stoss O, Stoilov P, Hartmann AM, Nayler O, Stamm S, (1999) The in vivo minigene approach to analyze tissue-specific splicing. Brain Res Brain Res Protoc 4: 383-394.
29. Abramoff MD, Magelhaes PJ, Ram SJ, (2004) Image Processing with ImageJ. Biophotonics International 11: 36-42.
30. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, et al. (2007) The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 14: 185-193.
31. Chabot B, LeBel C, Hutchison S, Nasim FH, Simard MJ, (2003) Heterogeneous nuclear ribonucleoprotein particle A/B proteins and the control of alternative splicing of the mammalian heterogeneous nuclear ribonucleoprotein particle A1 pre-mRNA. Prog Mol Subcell Biol 31: 59-88.
32. Hinman MN, Lou H, (2008) Diverse molecular functions of Hu proteins. Cell Mol Life Sci 65: 3168-3181.
33. Markus MA, Heinrich B, Raitskin O, Adams DJ, Mangs H, et al. (2006) WT1 interacts with the splicing protein RBM4 and regulates its ability to modulate alternative splicing in vivo. Exp Cell Res 312: 3379-3388.
34. Sawicka K, Bushell M, Spriggs KA, Willis AE, (2008) Polypyrimidine-tract-binding protein: a multifunctional RNA-binding protein. Biochem Soc Trans 36: 641-647.
35. Graveley BR, Hertel KJ, Maniatis T, (2001) The role of U2AF35 and U2AF65 in enhancer-dependent splicing. RNA 7: 806-818.
36. Allard JS, Perez E, Zou S, de Cabo R, (2009) Dietary activators of Sirt1. Mol Cell Endocrinol 299: 58-63.
37. Markus MA, Morris BJ, (2008) Resveratrol in prevention and treatment of common clinical conditions of aging. Clin Interv Aging 3: 331-339.
38. Cartegni L, Hastings ML, Calarco JA, de Stanchina E, Krainer AR, (2006) Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. Am J Hum Genet 78: 63-77.
39. Jumaa H, Nielsen PJ, (2000) Regulation of SRp20 exon 4 splicing. Biochim Biophys Acta 1494: 137-143.
40. Schroeder R, Waldsich C, Wank H, (2000) Modulation of RNA function by aminoglycoside antibiotics. EMBO J 19: 1-9.
41. Long JC, Caceres JF, (2009) The SR protein family of splicing factors: master regulators of gene expression. Biochem J 417: 15-27.
42. Leiro JM, Varela M, Piazzon MC, Arranz JA, Noya M, et al. (2010) The anti-inflammatory activity of the polyphenol resveratrol may be partially related to inhibition of tumour necrosis factor-alpha (TNF-alpha) pre-mRNA splicing. Mol Immunol 47: 1114-1120.
43. Gurusamy N, Lekli I, Mukherjee S, Ray D, Ahsan MK, et al. (2010) Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway. Cardiovasc Res 86: 103-112.
44. Holz MK, Ballif BA, Gygi SP, Blenis J, (2005) mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 123: 569-580.
45. van der Vos KE, Coffer PJ, (2008) FOXO-binding partners: it takes two to tango. Oncogene 27: 2289-2299.